

2018 Eosinophilic Esophagitis Drug Development- Pipeline Analysis Report

<https://marketpublishers.com/r/2145D16AF44EN.html>

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 2145D16AF44EN

Abstracts

Eosinophilic Esophagitis (EoE) represents the allergic inflammation of the esophagus that is caused by antigens in both children and adults. It is characterized by esophageal dysfunction and eosinophil infiltration. With increasing incidence and prevalence of the disease, research activities focusing on understanding the disease and development of treatment options are increasing significantly.

Around 15 companies and universities are focusing on developing treatment options for Eosinophilic Esophagitis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Eosinophilic Esophagitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Eosinophilic Esophagitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Eosinophilic Esophagitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of Figures

1.2 List of Tables

2 EOSINOPHILIC ESOPHAGITIS PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview

2.2 Eosinophilic Esophagitis Pipeline Snapshot

2.3 Eosinophilic Esophagitis Pipeline by Phase

2.4 Eosinophilic Esophagitis Pipeline by Company

2.5 Eosinophilic Esophagitis Pipeline by Mechanism of Action

3 EOSINOPHILIC ESOPHAGITIS- COMPANY WISE PIPELINE ANALYSIS

Adare Pharmaceuticals

Biotica Pharmaceuticals

Celgene Corp

DBV Technologies

Dr Falk Pharma

Glycan Biosciences

Quorum Innovations LLC

Sanofi

Shire Plc

4 EOSINOPHILIC ESOPHAGITIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details

Therapeutic Candidate Name

Originator

Co-Developer/License Partner

Orphan Drug Designation

Development Phase

Mechanism of Action

Current Status

Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN EOSINOPHILIC ESOPHAGITIS PIPELINE

6 APPENDIX

6.1 About VPA Research

6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018

Figure 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018

Figure 3: Company Wise Pipeline Drug Phases, H1- 2018

Figure 4: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018

Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

List Of Tables

LIST OF TABLES

- Table 1: Eosinophilic Esophagitis Pipeline by Phase, H1- 2018
- Table 2: Eosinophilic Esophagitis Pipeline by Companies, H1- 2018
- Table 3: Eosinophilic Esophagitis Pipeline by Mechanism of Action, H1- 2018
- Table 4: Adare Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
- Table 5: Biotica Pharmaceuticals Eosinophilic Esophagitis Pipeline, May 2018
- Table 6: Celgene Corp Eosinophilic Esophagitis Pipeline, May 2018
- Table 7: DBV Technologies Eosinophilic Esophagitis Pipeline, May 2018
- Table 8: Dr Falk Pharma Eosinophilic Esophagitis Pipeline, May 2018
- Table 9: Glycan Biosciences Eosinophilic Esophagitis Pipeline, May 2018
- Table 10: Quorum Innovations LLC Eosinophilic Esophagitis Pipeline, May 2018
- Table 11: Sanofi Eosinophilic Esophagitis Pipeline, May 2018
- Table 12: Shire Plc Eosinophilic Esophagitis Pipeline, May 2018

I would like to order

Product name: 2018 Eosinophilic Esophagitis Drug Development- Pipeline Analysis Report

Product link: <https://marketpublishers.com/r/2145D16AF44EN.html>

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2145D16AF44EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970